Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19 today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. finance.yahoo.com
Benitec Shares Skyrocket as Morgan Stanley Takes Stake $BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company. The stake amounts to 249,174 shares, or about $1.51 million. Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA...
Tired to fair for the price rising ? the moment is now .. let's rocket !
Morgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%! Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market. Market Cap of only 15.37M This is a 5X stock, Not trading advice as you know! :) This was a private call from my trading group and one of my top picks for March. You...
Catalyst Seneca Biopharma, Inc. (Nasdaq: SNCA) entered into a agreement with a privately held company Leading BioSciences, Inc. (“LBS” for a merger with to form Palisade Bio, Inc. SNCA has broken out of a descending channel and retested the upper trend line. The idea is self explanatory targets and stop loss is marked on the chart. A good risk management is...
Nanovector ASA Nordic Nanovector - Q4’20 report: Pace of recruitment for PARADIGME picking up
MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders...
MNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza...
SELB is back in the upper area of its high-traffic support/resistance from several times prior. Most recently, it saw this act as support in February. But it wasn't able to sustain the level. Anyway, it's back at this but in this case, the level has acted as a potential resistance (for now). It's gonna be interesting to see what happens next. Selecta seems to...
OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March? "Ongoing pressure from an activist investor to offload its BioReference unit...
Clovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus...
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs ·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation ·Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell...
Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline Extending the Cooperation in Pulmonary Arterial Hypertension $ZCMD yesterday announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education...
$ONCS Target 7.89 for 21.01% Or next add level is at 5.19 I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I...
MDT breakout through 120.05. This volatility contraction pattern is my bread and butter. With markets extended i'm not looking to push trades right now. But this set up is allowing a tight risk entry.
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE) $2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included finance.yahoo.com
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity. RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells...
MACD on Daily crossed Huge gap to fill Presentation the 18/03 -- globenewswire.com/news-release/2021/03/15/2192643/0/en/Amicus-Therapeutics-Announces-Presentation-and-Posters-at-the-2021-MDA-Clinical-Scientific-Conference.html big potential up